Interaction of Folate Intake and the Paraoxonase Q192R Polymorphism with Risk of Incident Coronary Heart Disease and Ischemic Stroke: The Atherosclerosis Risk in Communities Study

Annals of Epidemiology

Volumn 21, Issue 11, 2011, Pages 815-823

  Luu, Hung N ^a   Kingah, Pascal L ^b   North, Kari ^c   Boerwinkle, Eric ^a   Volcik, Kelly A ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b OAKWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^c IL   (United States)

Author keywords

Coronary Heart Disease; Folate; Genetic Polymorphism; Incidence; Stroke

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; FOLIC ACID;

ADULT; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; GENETIC VARIABILITY; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN INTAKE; VITAMIN METABOLISM;

ADULT; AFRICAN AMERICANS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; COHORT STUDIES; CORONARY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLIC ACID; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; STROKE; UNITED STATES;

EID: 80053521911     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2011.08.007     Document Type: Article

References (55)

1. The Atlas of Heart Disease and Stroke 2004, Maryad Edition Limited, Brighton. J. Mackay, G.A. Mensah (Eds.).
2. Verhaar M.C., Stroes E., Rabelink T.J. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 2002, 22:6-13.
3. McCully K.S. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969, 56:111-128.
4. McCully K.S., Wilson R.B. Homocysteine theory of arteriosclerosis. Atherosclerosis 1975, 22:215-227.
5. Ueland P.M., Refsum H., Beresford S.A., Vollset S.E. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000, 72:324-332.
6. Chasan-Taber L., Selhub J., Rosenberg I.H., et al. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996, 15:136-143.
7. Evans R.W., Shaten B.J., Hempel J.D., Cutler J.A., Kuller L.H. Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler Thromb Vasc Biol 1997, 17:1947-1953.
8. Folsom A.R., Nieto F.J., McGovern P.G., et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The atherosclerosis risk in communities (ARIC) study. Circulation 1998, 98:204-210.
9. Brattstrom L., Wilcken D.E., Ohrvik J., Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis. Circulation 1998, 98:26.
10. Verhoef P., Stampfer M.J., Buring J.E., et al. Homocysteine metabolism and risk of myocardial infarction: Relation with vitamins B6, B12, and folate. Am J Epidemiol 1996, 143:845-859.
11. Shimakawa T., Nieto F.J., Malinow M.R., Chambless L.E., Schreiner P.J., Szklo M. Vitamin intake: A possible determinant of plasma homocyst(e)ine among middle-aged adults. Ann Epidemiol 1997, 7:285-293.
12. Robinson K., Arheart K., Refsum H., et al. Low circulating folate and vitamin B6 concentrations: Risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC group. Circulation 1998, 97:437-443.
13. Rimm E.B., Willett W.C., Hu F.B., et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998, 279:359-364.
14. Loria C.M., Ingram D.D., Feldman J.J., Wright J.D., Madans J.H. Serum folate and cardiovascular disease mortality among US men and women. Arch Intern Med 2000, 160:3258-3262.
15. Voutilainen S., Rissanen T.H., Virtanen J., Lakka T.A., Salonen J.T. Low dietary folate intake is associated with an excess incidence of acute coronary events. Kuopio Ischemic Heart Disease Risk Factor Study. Circulation 2001, 103:2674-2680.
16. Bazzano L.A., He J., Ogden L.G., et al. Dietary intake of folate and risk of stroke in US men and women: NHANES I epidemiologic follow-up study. National Health and Nutrition Examination Survey. Stroke 2002, 33:1183-1188.
17. Larsson S.C., Mannisto S., Virtanen M.J., Kontto J., Albanes D., Virtamo J. Folate, vitamin B6, vitamin B12, and methionine intakes and risk of stroke subtypes in male smokers. Am J Epidemiol 2008, 167:954-961.
18. Van Guelpen B., Hultdin J., Johansson I., et al. Plasma folate and total homocysteine levels are associated with the risk of myocardial infarction, independently of each other and of renal function. J Intern Med 2009, 266:182-195.
19. Verhoef P., Kok F.J., Kruyssen D.A., et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997, 17:989-995.
20. Al-Delaimy W.K., Rexrode K.M., Hu F.B., et al. Folate intake and risk of stroke among women. Stroke 2004, 35:1259-1263.
21. Jakubowski H. Homocysteine-thiolactone and S-nitroso-homocysteine mediate incorporation of homocysteine into protein in humans. Clin Chem Lab Med 2003, 41:1462-1466.
22. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 1997, 272:1935-1942.
23. Jakubowski H., Ambrosius W.T., Pratt J.H. Genetic determinants of homocysteine thiolactonase activity in humans: Implications for atherosclerosis. FEBS Lett 2001, 491:35-39.
24. Perla-Kajan J., Jakubowski H. Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J 2010, 24:931-936.
25. Jakubowski H., Perla-Kajan J., Finnell R.H., et al. Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N-homocysteinylation in mice. FASEB J 2009, 23:1721-1727.
26. Mackness M.I., Mackness B., Durrington P.N. Paraoxonase and coronary heart disease. Atheroscler Suppl 2002, 3:49-55.
27. Ruiz J., Blanche H., James R.W., et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995, 346:869-872.
28. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995, 96:3005-3008.
29. Odawara M., Tachi Y., Yamashita K. Paraoxonase polymorphism (Gln192-arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997, 82:2257-2260.
30. Imai Y., Morita H., Kurihara H., et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000, 149:435-442.
31. Aydin M., Gencer M., Cetinkaya Y., et al. PON1 55/192 polymorphism, oxidative stress, type, prognosis and severity of stroke. IUBMB Life 2006, 58:165-172.
32. Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997, 17:1067-1073.
33. Agrawal S., Tripathi G., Prajnya R., et al. Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians. Indian J Med Sci 2009, 63:335-344.
34. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 2001, 21:1451-1457.
35. Domagala T.B., Lacinski M., Trzeciak W.H., Mackness B., Mackness M.I., Jakubowski H. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cell Mol Biol (Noisy-le-grand) 2006, 52:4-10.
36. Lansbury A.J., Catto A.J., Carter A.M., Bamford J.M., Grant P.J. The paraoxonase glutamine/arginine polymorphism and cerebrovacular disease. Cerebrovasc Dis 1997, 7:353-355.
37. Birjmohun R.S., Vergeer M., Stroes E.S., et al. Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; The EPIC-Norfolk prospective population study. PLoS One 2009, 4:e6809.
38. Lawlor D.A., Day I.N., Gaunt T.R., et al. The association of the PON1 Q192R polymorphism with coronary heart disease: Findings from the British Women's Heart and Health cohort study and a meta-analysis. BMC Genet 2004, 5:17.
39. Dahabreh I.J., Kitsios G.D., Kent D.M., Trikalinos T.A. Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysis. Genet Med 2010, 12:606-615.
40. The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. Am J Epidemiol 1989, 129:687-702. The ARIC Investigators.
41. White A.D., Folsom A.R., Chambless L.E., et al. Community surveillance of coronary heart disease in the atherosclerosis risk in communities (ARIC) study: Methods and initial two years' experience. J Clin Epidemiol 1996, 49:223-233.
42. Rosamond W.D., Folsom A.R., Chambless L.E., et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the atherosclerosis risk in communities (ARIC) cohort. Stroke 1999, 30:736-743.
43. Siedel J., Hagele E.O., Ziegenhorn J., Wahlefeld A.W. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983, 29:1075-1080.
44. Warnick G.R., Benderson J., Albers J.J. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982, 28:1379-1388.
45. ARIC Manual for Operation: No. 11-Sitting Blood Pressure and Postural Changes in Blood Pressure and Heart Rate 1987, National Heart Lung and Blood Institute, ARIC Coordinating Center, School of Public Health, University of North Carolina, Chapel Hill, NC.
46. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. atherosclerosis risk in communities study. N Engl J Med 2000, 342:905-912.
47. Willett W.C., Sampson L., Stampfer M.J., et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985, 122:51-65.
48. Composition of Foods. Agriculture Handbook no. 8 series 1975-1989, Human Nutrition Information Service, US Department of Agriculture, Washington, DC.
49. The ARIC Investigators. Derived Variables Dictionary: Visit 1. 2007. Available at: Accessed September 1, 2011. http://www.cscc.unc.edu/aric/pubuse/dictionary/cohort/DerVaribleDictonaryExam1.pdf.
50. Durand P., Prost M., Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 1996, 121:231-243.
51. Henning S.M., Swendseid M.E., Ivandic B.T., Liao F. Vitamins C, E and A and heme oxygenase in rats fed methyl/folate-deficient diets. Free Radic Biol Med 1997, 23:936-942.
52. Eikelboom J.W., Lonn E., Genest J., Hankey G., Yusuf S. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med 1999, 131:363-375.
53. Wald D.S., Law M., Morris J.K. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002, 325:1202.
54. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002, 288:2015-2022. Homocysteine Studies C.
55. Food standards: Amendments of standards of identity for enriched grain products to require addition of folic acid. Fed Regist 1996, 61:8781-8797. U.S. Food and Drug Administration.